

18 June 2024
AdAlta Limited (ASX:1AD)

Investor Webinar Invitations

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”) will be participating in the following two investor webinars over the coming week:

- A webinar hosted by Sharewise on Wednesday 19 June at 11:30am AEST
- An ASX Gems webinar, run by The Stock Network (TSN) on Friday 21 June, starting at 9.00am AEST.

These webinars will see AdAlta's CEO & Managing Director Dr Tim Oldham discuss:

- AdAlta's unique i-bodies® platform
- The diseases AdAlta's i-body® drug candidates are targeting
- AD-214, AdAlta's initial drug candidate, which is now on the cusp of Phase 2 clinical trials
- AdCella, AdAlta's new “east to west” cellular immunotherapy strategy
- AdAlta's strategic partnerships and how they are accelerating drug development
- Key target development milestones for the coming year

Sharewise Investor Webinar Registration Details

The investor webinar will be held on:

Wednesday 19 June 2024
11:30am AEST
Format: Zoom

AdAlta's CEO & Managing Director Dr Tim Oldham will also be taking questions from the audience at this event.

Please register in advance using the following link:

https://zoom.us/webinar/register/3017180804276/WN_cWxwuP43QsaUHhCGhI5KhQ#/registration

After registering, you will receive a confirmation email containing information about joining the webinar.

TSN ASX Gems Webinar Registration Details

The investor webinar will be held on:

Friday 21 June 2024
9.00am AEST
Format: YouTube

Please register in advance using the following link:

<https://www.eventbrite.com.au/e/the-stock-networks-asx-gems-tickets-920528765317?aff=oddtcreator>

This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited (ASX:1AD) is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body® technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody-enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body® technology creates a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by discovering and developing selected i-body®-enabled product candidates useful in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop these and other product candidates in a range of indications and product formats

AdAlta's current lead i-body® enabled candidate is AD-214, which is taking a wholly new approach to treat lung fibrosis (IPF) and other fibrotic diseases. In accord with its business model, AdAlta is creating a private, unlisted subsidiary called AdSolis to advance AD-214 into Phase II clinical trials through licensing and/or third-party investment.

AdAlta believes that the i-body® technology is ideally suited for use in the creation of advanced cellular immunotherapies for cancer and that this field represents an opportunity to expand its clinical stage pipeline. It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials and further enhancement with AdAlta's i-body® technology.

The Company is also entering collaborative discovery partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

For more information



Join our [InvestorHub](#)



Follow us on [Twitter](#)



Follow us on [LinkedIn](#)

To learn more about AdAlta please click here: www.adalta.com.au